Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Corcept Therapeutics (CORT) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Corcept Therapeutics (CORT) over the last 13 years, with Q3 2025 value amounting to $197.4 million.

  • Corcept Therapeutics' Operating Expenses rose 4521.66% to $197.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $675.6 million, marking a year-over-year increase of 3924.27%. This contributed to the annual value of $538.1 million for FY2024, which is 4345.48% up from last year.
  • According to the latest figures from Q3 2025, Corcept Therapeutics' Operating Expenses is $197.4 million, which was up 4521.66% from $167.8 million recorded in Q2 2025.
  • Over the past 5 years, Corcept Therapeutics' Operating Expenses peaked at $197.4 million during Q3 2025, and registered a low of $59.6 million during Q2 2021.
  • Over the past 5 years, Corcept Therapeutics' median Operating Expenses value was $90.8 million (recorded in 2023), while the average stood at $103.3 million.
  • As far as peak fluctuations go, Corcept Therapeutics' Operating Expenses plummeted by 277.4% in 2021, and later skyrocketed by 5098.71% in 2024.
  • Quarter analysis of 5 years shows Corcept Therapeutics' Operating Expenses stood at $62.2 million in 2021, then rose by 29.6% to $80.6 million in 2022, then rose by 28.77% to $103.7 million in 2023, then soared by 50.99% to $156.6 million in 2024, then rose by 26.04% to $197.4 million in 2025.
  • Its last three reported values are $197.4 million in Q3 2025, $167.8 million for Q2 2025, and $153.8 million during Q1 2025.